Dr. Thomas E. Gundersen is CEO and co-founder of Vitas and obtained his Master in organic analytical chemistry at the Department of Chemistry, University of Oslo in 1995, and later his Ph.D. (Dr. Philos) from the Depertment of Nutrition, Medical Faculty, University of Oslo. He has published a number of papers in the field of chromatographic determination of lipids, phytochemicals, vitamins and antioxidants.
One million DBS samples received, analyzed and reported
As of December 16, 2021 we have reached an important and noteworthy milestone. One million dried blood spot (DBS) samples have been sent from customers all around the world for analysis of different biomarkers. We currently receive 350 000 DBS sample annually with typical 25 % increase per year, and the rate is increasing from year to year as new customers and new assays are made available.
Test for covid-19 antibodies on Dried Blood Spots (DBS)
One newly discovered mutant of the SARS-CoV-2 virus is omicron. The scientific community is working intensely to clarify if the available vaccines protect against omicron, and if the rapid test antigen for the spike 1 protein recognizes the virus and with what sensitivity. Antibodies produced due to omicron infection may also be different from other mutations and undetectable with IgG assays based on the original spike 1 protein